ARAF Inhibitors
1 drugsAbout ARAF
ARAF is a serine/threonine-protein kinase in the RAF family, part of the RAS/MAPK signaling pathway that regulates cell growth and differentiation. Dysregulation of this pathway is common in cancers, leading to uncontrolled cell growth.
ARAF's role in the RAS/MAPK pathway makes it a compelling oncology target, though there is currently no genetic evidence directly linking ARAF to specific diseases.
One FDA-approved drug, ZELBORAF (Roche), targets the RAF family, demonstrating the clinical viability of modulating this pathway. ZELBORAF, a small molecule, was first approved in 2011 and is the only approved drug.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Non-small Cell Lung Cancer with only 2 trials.
Top Drugs
Roche is the only company with an approved drug targeting this pathway.
The market is highly concentrated, posing a barrier to entry.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ARAF, using small molecule modality.
Explore novel modalities to differentiate from existing therapies.
Clinical Trials 131 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 54 | 35 | 15 | 3 | 70% |
| Phase 2 | 62 | 24 | 14 | 24 | 63% |
| Phase 3 | 11 | 8 | 1 | 2 | 89% |
| Phase 4 | 4 | 2 | 2 | 0 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved ARAF drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting ARAF. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2011 - 2011)
The first and only drug, ZELBORAF, was approved in 2011.
The lack of recent approvals suggests a saturated market or challenges in developing new therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 57 clinical trials targeting ARAF.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities